Shin Tae-Hoon, Kim Hyung-Sik, Choi Soon Won, Kang Kyung-Sun
Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
Int J Mol Sci. 2017 Jan 25;18(2):244. doi: 10.3390/ijms18020244.
Inflammatory skin disorders that cause serious deterioration of the quality of life have become one of the major public concerns. Despite their significance, there is no fundamental cure to date. Mesenchymal stem cells (MSCs) possess unique immunomodulatory properties which make them a promising tool for the treatment of various inflammatory diseases. Our recent preclinical and clinical studies have shown that MSCs can be successfully used for the treatment of atopic dermatitis (AD), one of the major inflammatory skin diseases. This observation along with similar reports from other groups revealed the efficacy and underlying mechanisms of MSCs in inflammatory dermatosis. In addition, it has been proposed that cell priming or gene transduction can be novel strategies for the development of next-generation high-efficacy MSCs for treating inflammatory skin diseases. We discuss here existing evidence that demonstrates the regulatory properties of MSCs on immune responses under inflammatory conditions.
导致生活质量严重下降的炎症性皮肤病已成为主要的公共关注问题之一。尽管其意义重大，但迄今为止尚无根本治愈方法。间充质干细胞（MSCs）具有独特的免疫调节特性，这使其成为治疗各种炎症性疾病的有前途的工具。我们最近的临床前和临床研究表明，MSCs可成功用于治疗主要炎症性皮肤病之一的特应性皮炎（AD）。这一观察结果以及其他研究小组的类似报告揭示了MSCs在炎症性皮肤病中的疗效及潜在机制。此外，有人提出细胞预处理或基因转导可能是开发用于治疗炎症性皮肤病的下一代高效MSCs的新策略。我们在此讨论现有证据，这些证据证明了MSCs在炎症条件下对免疫反应的调节特性。
